Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study
Marlies E. J. Reinders, Koen E. Groeneweg, Sanne H. Hendriks, Jonna R. Bank, Geertje J. Dreyer, Aiko P. J. de Vries, Melissa van Pel, Helene Roelofs, Volkert A.L. Huurman, Paula Meij, Dirk Jan A. R. Moes, Willem E. Fibbe, Frans H.J. Claas, Dave L. Roelen, Cees van Kooten, Jesper Kers, Sebastiaan Heidt, Ton J. Rabelink, Johan W. de Fijter
Topics & Concepts
MedicineTacrolimusMesenchymal stem cellOpen labelSingle CenterBone marrowRandomized controlled trialStromal cellSurgeryInternal medicineTransplantationPathologyMesenchymal stem cell researchTissue Engineering and Regenerative MedicineHematopoietic Stem Cell Transplantation